Somatostatin and diabetes
- PMID: 6111219
- DOI: 10.1016/0002-9343(81)90584-2
Somatostatin and diabetes
Abstract
Somatostatin, a tetradecapeptide originally isolated from the hypothalamus on the basis of its ability to inhibit the secretion of growth hormone, is now known to be widely distributed in various endocrine and gastrointestinal tissues and to have diverse actions, including inhibition of insulin and glucagon secretion. The location of somatostatin in pancreatic islet D cells suggests that it may act as a local regulator of insulin and glucagon secretion. Changes in islet D-cell function in experimentally-induced and spontaneous diabetes in animals suggest that the peptide may be involved in the pathogenesis of diabetes. Clinical studies with the peptide have provided insight into the physiologic roles of glucagon and growth hormone, and have indicated a potential therapeutic use for somatostatin in diabetes in man.
Similar articles
-
Somatostatin. Its possible role in carbohydrate homeostasis and the treatment of diabetes mellitus.Arch Intern Med. 1977 May;137(5):659-66. doi: 10.1001/archinte.137.5.659. Arch Intern Med. 1977. PMID: 324423
-
[The historic role of insulin in the physiopathology of the metabolic complications from pancreatic diabetes. Therapeutic implications for somatostatin].C R Acad Hebd Seances Acad Sci D. 1975 May 26;280(20):2353-6. C R Acad Hebd Seances Acad Sci D. 1975. PMID: 807423 French.
-
Somatostatin. Physiology and clinical applications.Med Clin North Am. 1978 Mar;62(2):375-92. doi: 10.1016/s0025-7125(16)31813-2. Med Clin North Am. 1978. PMID: 347198 Review. No abstract available.
-
Suppression of pancreatic endocrine tumour secretion by long-acting somatostatin analogue.Lancet. 1979 Oct 13;2(8146):764-7. doi: 10.1016/s0140-6736(79)92115-9. Lancet. 1979. PMID: 90860
-
Somatostatin and the endocrine pancreas.Curr Top Mol Endocrinol. 1976;3:127-43. doi: 10.1007/978-1-4684-2598-7_9. Curr Top Mol Endocrinol. 1976. PMID: 211005 Review.
Cited by
-
Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients.J Endocrinol Invest. 1988 Jul-Aug;11(7):501-7. doi: 10.1007/BF03350169. J Endocrinol Invest. 1988. PMID: 3049768
-
The relationship between N-terminal prosomatostatin, all-cause and cardiovascular mortality in patients with type 2 diabetes mellitus (ZODIAC-35).BMC Endocr Disord. 2015 Apr 14;15:19. doi: 10.1186/s12902-015-0009-2. BMC Endocr Disord. 2015. PMID: 25880900 Free PMC article.
-
Is Diabetes Mellitus a Predisposing Factor for Helicobacter pylori Infections?Curr Diab Rep. 2023 Aug;23(8):195-205. doi: 10.1007/s11892-023-01511-5. Epub 2023 May 22. Curr Diab Rep. 2023. PMID: 37213058 Review.
-
Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients.J Endocrinol Invest. 2012 Apr;35(4):372-7. doi: 10.3275/7770. Epub 2011 May 31. J Endocrinol Invest. 2012. PMID: 21642764
-
Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man.J Clin Invest. 1984 Feb;73(2):405-11. doi: 10.1172/JCI111226. J Clin Invest. 1984. PMID: 6142057 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
